Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)
arcticnovartis
- In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21
- SD is most prevalent type of chronic inducible urticaria (CIndU)2; more than 50% of patients remain symptomatic despite taking H1 antihistamines3
- Rhapsido showed safety profile in SD consistent with CSU, with no routine lab monitoring required1